BMC surgery · 2025
Radiofrequency rhizotomy for multiple sclerosis-related trigeminal neuralgia: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hajikarimloo Bardia, Tos Salem M, Mohammadzadeh Ibrahim, Najari Dorsa, Ebrahimi Azin, Hasanzade Arman, Ghorbanpouryami Fatemeh, Habibi Mohammad Amin
Аннотация
BACKGROUND: Radiofrequency rhizotomy (RFR) is one of the primary therapeutic options for managing patients suffering from multiple sclerosis-related trigeminal neuralgia (MS-TN). Given the increasing use of RFR for MS-TN and the absence of consensus on its efficacy, we aimed to assess the clinical application of RFR in this patient population.
METHODS: On April 7, 2025, we conducted a systematic literature search. Studies that evaluated the pain-related outcomes of RFR in MS-TN patients were included.
RESULTS: Fifteen studies involving 278 MS-TN patients who received RFR were included. The meta-analysis revealed a pooled pain-free rate and adequate pain-relief rate of 78% (95% CI: 58%-93%) and 96% (95% CI: 89%-100%) at the initial follow-up. In addition, the meta-analysis demonstrated a pooled pain-free rate and adequate pain-relief rate of 64% (95% CI: 25%-95%) and 86% (95% CI: 63%-99%), respectively, at the last follow-up. The pooled complication rate in our study was 9% (95% CI: 1%-22%).
CONCLUSIONS: RFR is associated with substantial immediate pain relief rates, reasonable complication rates, and favorable long-term pain-related outcomes. However, the long-term outcomes show considerable variability and should be interpreted cautiously. RFR can be considered one of the main therapeutic options for patients suffering from MS-TN, where the pain has limited their daily performance.
METHODS: On April 7, 2025, we conducted a systematic literature search. Studies that evaluated the pain-related outcomes of RFR in MS-TN patients were included.
RESULTS: Fifteen studies involving 278 MS-TN patients who received RFR were included. The meta-analysis revealed a pooled pain-free rate and adequate pain-relief rate of 78% (95% CI: 58%-93%) and 96% (95% CI: 89%-100%) at the initial follow-up. In addition, the meta-analysis demonstrated a pooled pain-free rate and adequate pain-relief rate of 64% (95% CI: 25%-95%) and 86% (95% CI: 63%-99%), respectively, at the last follow-up. The pooled complication rate in our study was 9% (95% CI: 1%-22%).
CONCLUSIONS: RFR is associated with substantial immediate pain relief rates, reasonable complication rates, and favorable long-term pain-related outcomes. However, the long-term outcomes show considerable variability and should be interpreted cautiously. RFR can be considered one of the main therapeutic options for patients suffering from MS-TN, where the pain has limited their daily performance.